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Abstract
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Background: Ischemia with no obstructive coronary artery disease (INOCA) is common and has
an adverse prognosis. We set out to describe the natural history of symptoms and ischemia in
INOCA.
Methods: CIAO-ISCHEMIA (Changes in Ischemia and Angina over One year in ISCHEMIA
trial screen failures with INOCA) was an international cohort study conducted from 2014-2019
involving angina assessments (Seattle Angina Questionnaire [SAQ]) and stress echocardiograms
1-year apart. This was an ancillary study that included patients with history of angina who were
not randomized in the ISCHEMIA trial. Stress-induced wall motion abnormalities were
determined by an echocardiographic core laboratory blinded to symptoms, coronary artery
disease (CAD) status and test timing. Medical therapy was at the discretion of treating
physicians. The primary outcome was the correlation between changes in SAQ Angina
Frequency score and change in echocardiographic ischemia. We also analyzed predictors of 1year changes in both angina and ischemia, and compared CIAO participants with ISCHEMIA
participants with obstructive CAD who had stress echocardiography before enrollment, as CIAO
participants did.
Results: INOCA participants in CIAO were more often female (66% of 208 vs. 26% of 865
ISCHEMIA participants with obstructive CAD, p<0.001), but the magnitude of ischemia was
similar (median 4 ischemic segments [IQR 3-5] both groups). Ischemia and angina were not
significantly correlated at enrollment in CIAO (p=0.46) or ISCHEMIA stress echocardiography
participants (p=0.35). At 1 year, the stress echocardiogram was normal in half of CIAO
participants and 23% had moderate or severe ischemia (≥3 ischemic segments). Angina
improved in 43% and worsened in 14%. Change in ischemia over one year was not significantly
correlated with change in angina (rho=0.029).
Conclusions: Improvement in ischemia and improvement in angina were common in INOCA,
but not correlated. Our INOCA cohort had a similar degree of inducible wall motion
abnormalities to concurrently enrolled ISCHEMIA participants with obstructive CAD. Our
results highlight the complex nature of INOCA pathophysiology and the multifactorial nature of
angina.
Clinical Trial Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT02347215
Key Words: INOCA, stress testing, angina
Non-standard Abbreviations and Acronyms
CIAO = Changes in Ischemia and Angina over One year among ISCHEMIA trial screen failures
with no obstructive CAD on CCTA
CCTA = coronary computed tomography angiography
CorMicA = Coronary Microvascular Angina
INOCA = ischemia with no obstructive coronary artery disease
ISCHEMIA = International Study of Comparative Health Effectiveness with Medical and
Invasive Approaches
MINOCA = myocardial infarction with non-obstructive coronary arteries
SAQ = Seattle Angina Questionnaire
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Clinical Perspective

What is new?
•

Patients with moderate or severe ischemia on stress echocardiography and no obstructive
CAD in this study (INOCA) were more often female, but had largely similar ischemia
compared to obstructive CAD patients (median 4 segments).

•

Half of 1-year INOCA stress echocardiograms were normal and 23% had moderate or
severe ischemia at 1 year (≥3 ischemic segments). Angina improved in 43% and
worsened in 14%.

•

Ischemia and angina were not correlated in those with INOCA or with obstructive CAD
at baseline, and change in ischemia was not correlated with change in angina in INOCA
patients.

What are the clinical implications?
•

It is common for ischemia and angina to improve in INOCA, but the two may not be
linked, because pathophysiology of angina is complex.

Downloaded from http://ahajournals.org by on July 20, 2021

•

Ischemia severity on stress echocardiography is not an adequate surrogate for symptom
severity either in patients with INOCA or in patients with obstructive CAD. Clinicians
should focus on symptom management in order to maximize patients’ quality of life.
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Introduction
Among stable patients referred to cardiac catheterization for evaluation of suspected coronary
artery disease (CAD), 20-65% have no obstructive stenoses.1, 2 When documented myocardial
ischemia occurs with no coronary stenoses ≥50%, the diagnosis of Ischemia with No Obstructive
Coronary Artery disease (INOCA) is established. This condition has been associated with (a) an
increased risk of death, myocardial infarction and stroke, compared to the general population,1, 35

especially in those who remain symptomatic6 or have mild-moderate atherosclerosis,7,8 (b)

persistent chest pain by 1 year in half of patients, with a 20% 5-year risk of hospitalization for
chest pain, and (c) high healthcare costs, estimated at nearly $770,000 lifetime cost per patient.9
Despite these adverse outcomes, the underlying mechanisms responsible for symptoms and
ischemia are unclear; impaired coronary flow reserve (CFR) and/or inducible coronary artery
spasm have been documented in some patients.10-14 Event rates may be higher in patients with
Downloaded from http://ahajournals.org by on July 20, 2021

evidence of inducible ischemia, e.g., on stress echocardiography, though this was not the case in
a large European series.7, 8, 15-17 Whether myocardial ischemia is solely responsible for angina
symptoms in this population is uncertain. The treatment for patients with INOCA is highly
variable in clinical practice, with guidelines focusing on symptom management.18 19, 20 Better
understanding of the relationship between ischemia and health status (i.e., symptoms, physical
functioning and quality of life) in patients with INOCA is needed.
To address this gap, we leveraged the enrollment process of the International Study of
Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial,
which recruited patients with moderate or severe inducible ischemia. To assess trial eligibility,
coronary CT angiography (CCTA) was performed in most participants, of whom 21% had no
obstructive CAD meeting criteria for randomization, and were excluded.21 These participants
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were eligible for the Changes in Ischemia and Angina over One year among ISCHEMIA trial
screen failures with no obstructive CAD on CCTA (CIAO-ISCHEMIA, “CIAO”) ancillary
study, funded separately by the National Heart, Lung, and Blood Institute. The main objective of
CIAO were to analyze the natural history of symptoms and ischemia in INOCA patients. We
compared clinical characteristics of patients with INOCA to those with obstructive CAD,
collected in a unified trial program. We also explored relationships among symptoms, ischemia,
and medication use.

Methods
The data that support the findings of this study are available from the corresponding author upon
reasonable request.
CIAO participants underwent stress echocardiography 1 year after the initial stress
Downloaded from http://ahajournals.org by on July 20, 2021

echocardiogram done to qualify participants for the ISCHEMIA trial. CIAO participants were
also assessed for angina-related health status using the Seattle Angina Questionnaire at
enrollment and at 6 months and 1 year from the initial stress echocardiogram.
We compared clinical characteristics, quality of life and stress echocardiographic findings
between CIAO participants and the subset of ISCHEMIA participants who were randomized in
ISCHEMIA after a CCTA demonstrated obstructive CAD (Figure 1). This comparison aimed to
investigate how the associations of ischemia and symptoms might differ between patients with
and without obstructive CAD. Within CIAO, we analyzed the relationships between symptoms,
ischemia and atherosclerosis severity on CCTA, and examined changes in angina severity and
ischemia severity over 1 year. We also compared the 1-year rate of clinical endpoint events
between CIAO and ISCHEMIA participants.
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The primary outcome was the correlation between change in angina and the change in the
number of ischemic segments on stress echocardiography over 1 year. The study was approved
by the NYU Grossman School of Medicine Institutional Review Board, and by each site’s local
institutional review board or ethics committee. All patients provided informed consent.
Participant Eligibility
CIAO
Patients with chronic stable ischemia who were ineligible for ISCHEMIA due to non-obstructive
atherosclerosis or entirely normal arteries on CCTA were considered for CIAO if they had
ischemic symptoms before or during stress echocardiography21 (Figure 1). Ischemic symptoms
could include chest pain or anginal equivalent symptoms such as shortness of breath. We
restricted CIAO to patients who had stress echocardiography to eliminate the potential for
heterogeneity from different stress testing modalities at various sites.
Downloaded from http://ahajournals.org by on July 20, 2021

ISCHEMIA trial comparator group
Inclusion criteria for the ISCHEMIA trial appear in Table I in the Supplement.22 For comparison
to patients enrolled in CIAO, we considered ISCHEMIA trial participants randomized to either
arm who had been enrolled after a qualifying stress echocardiogram and who had at least 50%
stenosis of a coronary artery (“obstructive CAD”) on CCTA. This approach maximized
comparability of ischemia testing between patients with and without obstructive CAD. This
comparison was included here to put into context the CIAO results with findings in patients with
obstructive CAD who had the same type of qualifying stress test, stress echocardiography.
Stress Echocardiographic Ischemia Assessment
Stress echocardiograms were interpreted at the Massachusetts General Hospital core laboratory,
blinded to clinical parameters, stress ECG and CCTA results. The core laboratory was blinded as
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to whether participants were enrolled in ISCHEMIA or CIAO, which was possible because the
same study number scheme was used for both. Further, CIAO 1-year stress echocardiograms
were analyzed while the ISCHEMIA trial was still enrolling, hence the core laboratory was
unaware if a test was a CIAO or ISCHEMIA qualifying stress test or a CIAO follow-up
examination. Ischemia severity was defined by the number of segments with stress-induced
moderate or severe wall motion abnormalities.23 The ISCHEMIA trial protocol did not include
repeat stress testing. Stress wall motion score index was calculated as follows: each of 16 left
ventricular segments was associated a wall motion score on post-stress imaging (1 = normal or
hyperkinetic, 2 = hypokinetic, 3 = akinetic, 4 = dyskinetic) and scores were averaged over the
segments.24
To assess inter- and intra-observer variability at the core laboratory, the core laboratory
director read 62 stress echocardiograms (36 from enrollment, 26 follow-up) a second time, and a
Downloaded from http://ahajournals.org by on July 20, 2021

second reader interpreted 12 stress echocardiograms, all while blinded to the initial reading. We
tested the null hypothesis of no systematic differences in the inter- and intra-observability
agreement measurements using McNemar’s exact test.25 Intra-observer agreement at the core
laboratory was 96.8% for positive vs. negative stress echocardiography, and 95.1% for moderate
or severe vs. mild ischemia. There was no evidence for systematic differences between readings
(p=0.50 for positive vs. negative and p=0.25 for moderate or severe ischemia). Inter-observer
agreement for positive vs. negative stress echocardiography and for moderate or severe vs. mild
ischemia was 100%.
Health Status Assessments
CIAO participants had assessment of their angina at enrollment, 6 months and at 1 year using the
7-item Seattle Angina Questionnaire (SAQ), which quantifies patients’ symptoms of angina,
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physical limitations due to angina and angina-related quality of life over the past month.26 The 3
domains are averaged to define a SAQ Summary Score capturing all domains in the 4 weeks
preceding enrollment. The 6-month visit was not required. Scores range from 0-100 with higher
scores indicating fewer symptoms and better health status. The Rose Dyspnea Questionnaire and
EQ-5D were also obtained.27, 28
Clinical Outcomes
We collected the following site-reported events over 1 year of follow up: myocardial infarction,
unstable angina, heart failure, stroke, resuscitated cardiac arrest, death, chest pain hospitalization.
These events were defined as in the ISCHEMIA trial29 with the addition of chest pain
hospitalization, which was defined as an overnight stay in a hospital with the discharge diagnosis
of chest pain.
Statistical Analyses
Downloaded from http://ahajournals.org by on July 20, 2021

We computed descriptive statistics of baseline clinical characteristics, medications, stress test
results and symptoms, presented as median and inter-quartile range (IQR), or frequency and
percentage, as appropriate. Categories for each variable are shown in the tables. We evaluated
differences in study variables between patients with INOCA and obstructive CAD using the
Wilcoxon rank-sum test or Student’s t-test (as appropriate) for continuous variables, and the
Pearson’s chi-square test or McNemar’s test (as appropriate) for categorical variables. Findings
on stress echocardiography and symptoms were similarly compared between enrollment and 1
year, and enrollment, 6 months, and 1 year, respectively. Correlations were measured using
Spearman correlation coefficients.
To assess the relationship of symptoms, degree of ischemia, and medication usage in
CIAO participants, we examined change in SAQ Summary Score and the SAQ Angina
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Frequency and Physical Limitation subscale scores as binary outcomes based on clinically
relevant definitions of improvement (≥5 points for summary score and ≥10 for subscale scores)30
and continuously, measured as the difference between scores at follow-up and enrollment.
Similarly, we examined ischemia on stress echocardiography in a continuous and a binary
outcome setting. We calculated the change in the number of ischemic segments as the difference
between 1 year and enrollment. We defined binary variables of improvement: reduction by at
least 2 ischemic segments; and normalization, defined as zero ischemic segments at 1 year.
For continuously measured SAQ scores (at enrollment, 6 months and 1 year), we used
linear mixed models with patient as the cluster variable to estimate associations with the change
in number of ischemic segments over 1 year. We fit three sets of models in which we
sequentially adjusted for covariates. In the first, we adjusted for visit timing, the number of
ischemic segments at enrollment and the change in the number of ischemic segments over time.
Downloaded from http://ahajournals.org by on July 20, 2021

In the second, we controlled for hypothesized confounders, namely, age, sex, hypertension,
diabetes, and segment stenosis score as a measure of non-obstructive atherosclerosis severity on
CCTA.31 Finally, we included medications which, to mitigate the limitations of small sample
sizes, we grouped into the following classes: beta blockers, anti-anginal medications other than
beta blockers (e.g., calcium channel blockers, long-acting nitrates and ranolazine), angiotensin
converting enzyme inhibitors or angiotensin receptor blockers (ACEI/ARB), and statins. Then,
we constructed categories to represent patterns of use. Each medication class was defined as a
binary variable equal to 1 if a patient was always on medications in the class over follow-up, or
started taking them by the 1-year visit; and 0 if a patient never used the medication class during
the study period, or stopped it by the 1-year visit. Binary outcomes of improvement in symptoms
were analogously analyzed using logistic regression.
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For continuously measured number of ischemic segments (measured at 1 year), we used
linear regression modeling of the change from enrollment and logistic regression modeling of the
binary outcomes of improvement. In initial modeling, we assessed the association of the number
of ischemic segments with medication usage by including the medication classes (as previously
defined) simultaneously. Then, we extended the models to adjust for patient-level risk factors as
noted above.
For regression analyses, we created multiply imputed datasets using classification and
regression tree methods in the MICE package in R32 and pooled results from each dataset
together using Rubin’s formula. Descriptive analyses include available data, whereas results
from regression analyses are based on the multiply imputed datasets.
Power was projected at 80% to detect a difference in median SAQ Summary Score of
≥8.5 points between groups of participants with vs. without ischemia improvement over 1 year,
Downloaded from http://ahajournals.org by on July 20, 2021

for 198 paired assessments, with an assumed standard deviation of 20 based on the prior
literature.33 Ischemia improvement was defined as reduction by at least 2 in the number of
ischemic segments from enrollment to 1 year. The null hypothesis was that change in SAQ
would not be correlated with ischemia improvement in CIAO participants, and the alternative
hypothesis was that these two change parameters would be significantly correlated. Alpha was
set at 0.05, with two-sided testing for all analyses.
The time to event was calculated from ISCHEMIA enrollment for both CIAO and ISCHEMIA
participants, since this was a time point common to both cohorts.
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Results
Patient Characteristics: CIAO (INOCA) and ISCHEMIA (Obstructive CAD)
There were 208 eligible INOCA participants enrolled in CIAO between July 2014-July 2018 at
39 sites in 11 countries (Figure 1). These were compared to 865 ISCHEMIA randomized trial
participants with obstructive CAD on study CCTA who underwent echocardiographic stress
testing.
INOCA participants were much more likely to be female than obstructive CAD
participants who qualified by stress echocardiography (66% vs. 26%, p<0.001, Table 1). INOCA
participants were younger (median 63 years, interquartile range [IQR 56-70] years vs. 66 years
[IQR 59-72], p=0.001) and were more likely to be non-Hispanic Whites and less likely to be
non-Hispanic Asians. INOCA participants were less likely to have diabetes, prior MI and current
or former smoking history but more likely to have history of depression. On study CCTA, 23%
Downloaded from http://ahajournals.org by on July 20, 2021

had no evident atherosclerosis and 77% had non-obstructive atherosclerosis.
Indications for Stress Echocardiography
The most common indication for initial stress testing in CIAO was chest pain, in 77%.
Indications for initial stress testing were (not mutually exclusive): typical chest pain (n=104,
50%), atypical chest pain (n=67, 32%), shortness of breath (n=102, 49%), discomfort in the arm,
neck, jaw or throat (n=17, 8%), abdominal discomfort (n=6, 3%), fatigue (n=29, 14%), nausea or
other gastrointestinal upset (n=5, 2%), sweating (n=9, 4%), screening with no symptoms (n=4,
2%), other (n=3, 1%, Table 1). The indication for initial stress testing was not collected in
ISCHEMIA participants. Only 18 stress echocardiograms were performed for screening or other
reasons.
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Medication Use at Enrollment
At the time of enrollment, 122 INOCA participants (59%) were taking a beta blocker (Table II in
the Supplement) and 57 (28%) any antianginal medication other than beta blocker. At
enrollment, 41% were taking ACEI or ARB, 82% a statin, and 78% an antiplatelet agent or
anticoagulant. Laboratory values are shown in Table II in the Supplement.
Stress Echocardiography Findings at Enrollment
The median number of ischemic segments on the qualifying stress echocardiogram was 4 (IQR
3-5, Table 2, Figure 2) in both INOCA and obstructive CAD participants from ISCHEMIA, with
more obstructive CAD participants having very severe ischemia (p=0.012, Figure 2). Anterior
ischemia was frequent, and was less common with obstructive CAD (35% vs. 44% of INOCA,
p=0.027). The enrollment test utilized exercise in 167 (82%) INOCA patients and 621 (82%)
CAD patients (Table 1). A sample INOCA case showing severe ischemia at enrollment is shown
Downloaded from http://ahajournals.org by on July 20, 2021

in Videos A and B.
Health Status at Enrollment
At enrollment, the median SAQ summary score was higher in INOCA than obstructive CAD
participants, though both groups had good baseline health status (Figure 2, Table 3). Angina
frequency was similar over the 4 weeks preceding enrollment, with 16% of INOCA participants
having angina weekly or more often vs. 20% of those with CAD, and 40% reporting no angina in
the month prior to enrollment in INOCA vs. 37% in obstructive CAD, p=0.62 (Table 3). Of note,
even those INOCA patients reporting no angina in the 4 weeks preceding enrollment had
ischemic symptoms either before or during the stress echocardiogram. Similarly, we have
previously reported that in ISCHEMIA, 90% of participants had a history of angina, but 35%
reported no angina in the 4 weeks preceding enrollment.34
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Characteristics of INOCA patients based on the presence or absence of any atherosclerosis
on CCTA
INOCA patients with any atherosclerosis on CCTA were older and had lower eGFR than those
without any atherosclerosis, and were more likely to have diabetes, with no difference in SAQ
scores at enrollment (Table III in the Supplement). There were no differences in stress test
parameters between these groups (Table IV in the Supplement).
Association of Inducible Ischemia and Health Status in Participants with and without
Obstructive CAD at Enrollment
At enrollment, there was no significant correlation between the number of ischemic segments on
stress echocardiography and SAQ Angina Frequency subscale score for either INOCA or
obstructive CAD participants (Figure 2). There was also no significant correlation between SAQ
Summary Score and the number of ischemic segments in INOCA (rho=0.066, p=0.37) or
Downloaded from http://ahajournals.org by on July 20, 2021

obstructive CAD participants (rho=0.055, p=0.11).
Longitudinal Changes in Health Status with INOCA
At 1 year, the SAQ Angina Frequency subscale score improved by ≥10 points in 82 (43%) of
INOCA participants, with 117 (59%) reporting no angina in the prior month (Table 3). Angina
frequency worsened from enrollment to 1 year by ≥10 points in 27 (14%). At 1 year, SAQ7
summary score improved by ≥5 points in 96 (50%) INOCA participants and worsened by ≥5
points in 39 (20%). Angina-related health status improved from enrollment to 6 months, without
significant incremental improvement from 6 months to 1 year.
Medication use at 1 year is shown in Table II in the Supplement. The median number of
anti-anginal agents was 1 at enrollment and at 1 year. Beta blockers were used in the majority of
participants at all time points. The use of antianginal medications other than beta blockers tended
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to increase over time, while use of statins decreased. There was no significant change from
enrollment to 1 year in the use of ACEI/ARBs or in use of antiplatelet agents.
Longitudinal Changes in Ischemia in INOCA
Among 192 CIAO participants who completed the 1-year stress echocardiogram, half had
normal stress echocardiography. At 1 year, the median number of ischemic segments was 0 (IQR
0-2). Moderate or severe ischemia was present in 44 (23%). The distribution of change in
ischemia from enrollment to 1 year is shown in Figure 3. 132 (68%) had reduction of at least 2
ischemic segments. 40 (21%) of 1-year stress echocardiograms were abnormal and had not
improved by at least 2 ischemic segments.
Correlation between Change in Ischemia and Change in Health Status
Participants with 1-year improvement of at least 2 ischemic segments on stress echocardiography
had similar 1-year SAQ summary scores to those without this degree of improvement (median 92
Downloaded from http://ahajournals.org by on July 20, 2021

[IQR 81-97] vs. 89 [IQR 70-100], p=0.56). There was also no difference between these groups in
angina frequency at 1 year (100 [IQR 90-100] vs. 100 [IQR 80-100], p=0.75) and 1-year SAQ
physical limitation scores (100 [IQR 83-100] vs. 100 [IQR 67-100], p=0.23).
There was no relationship between 1-year change in angina and 1-year change in ischemia in
CIAO as measured by the number of segments on stress echocardiography with stress-induced
wall motion abnormalities (Figure 4).
Additional analyses explored the correlation between change in ischemia and angina
among subgroups defined by exercise stress echocardiography at baseline, peak heart rate >85%
of the maximum predicted, stress testing indication of typical chest pain, symptoms elicited
during initial stress echocardiogram and SAQ <100 at enrollment, but revealed no statistically
significant correlation between changes in ischemia and angina in any of these subgroups.
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Multivariable Analysis of Changes in Health Status and Ischemia, Including Medication
Use
On multivariable analysis, change in number of ischemic segments from enrollment to 1 year
was not statistically significantly associated with any health status outcomes (improvement in
SAQ summary score of ≥5 points: OR 0.93 per segment more ischemia at 1 year as compared to
enrollment, 95% CI 0.79-1.09, p=0.37; improvement in SAQ Angina Frequency subscale score
of ≥10 points: OR 0.85, 95% CI 0.71-1.02, p=0.08; improvement in SAQ Physical Limitation
subscale score of ≥10 points: OR 0.99, 95% CI 0.82-1.20, p=0.96) (Table V in the Supplement).
When analyzing change in SAQ from enrollment as a continuous variable, we did not observe
any association with change in the number of ischemic segments (Table VI in the Supplement).
Compared to patients without diabetes, patients with diabetes experienced 2.7 times the
odds of improvement by ≥2 ischemic segments, adjusting for other risk factors (Table VII in the
Downloaded from http://ahajournals.org by on July 20, 2021

Supplement). Diabetes was also associated with reduction in the number of ischemic segments
over time when analyzed as a continuous variable (Table VIII in the Supplement).
We did not observe evidence of association of angina-related health status with change in
number of ischemic segments, age, history of hypertension or diabetes, severity of
atherosclerosis on CCTA or medications (Table V in the Supplement) or in the models of
continuous change in symptoms over time (Table VI in the Supplement). Male sex was
associated with lower likelihood of change in SAQ scores over time.
Clinical Outcomes
Over 1 year in the CIAO cohort, the following clinical events occurred: 1 MI, 2 unstable angina
hospitalizations, 1 heart failure hospitalization, 5 chest pain hospitalizations and no resuscitated
cardiac arrests or deaths. Only one event occurred per participant. The 1-year cumulative event
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rate for the composite of death, MI, or hospitalization for heart failure or unstable angina was
2.06 per 100 participants (95% CI 0.68-4.88). This was lower than the cumulative event rate in
the ISCHEMIA stress echo obstructive CAD comparator group, 6.15 (95% CI 4.68-7.89),
p<0.0001 for comparison (Figure I in the Supplement). The 1-year cumulative event rate for the
composite of the above events plus chest pain hospitalization was also lower in CIAO as
compared to ISCHEMIA stress echo participants: 3.99 (95% CI 1.87-7.36) vs. 8.59 (95% CI
6.81-10.6), p=0.007 (Figure II in the Supplement).

Discussion
Given the prevalence of INOCA and limited evidence regarding how to manage patients with
INOCA, we sought to describe the natural history of ischemia and health status, and the
correlation between the two, in a well-characterized clinical cohort. In this international, multiDownloaded from http://ahajournals.org by on July 20, 2021

center observational study, patients with INOCA and those with obstructive CAD were selected
using the same stress test and clinical eligibility criteria, and all stress echocardiograms were
interpreted by the same, blinded core laboratory. In half of INOCA cases, the 1-year stress
echocardiogram was normal, and in 23%, there was moderate or severe ischemia at 1 year.
Angina frequency decreased by a clinically meaningful amount in 43%, despite little change in
anti-anginal medications. There was no significant correlation between change in ischemia and
change in angina.
The most striking difference between INOCA and obstructive CAD cohorts was the
female predominance of INOCA. INOCA and obstructive CAD patients had a largely similar
number of ischemic segments on stress echocardiography at enrollment. INOCA patients were
slightly younger, with lower rates of diabetes, prior MI and smoking history and higher
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frequency of depression. INOCA patients had similar angina frequency, but overall anginarelated quality of life was worse in patients with obstructive CAD. Angina was predominantly
mild, owing to exclusion of patients with an unacceptable degree of angina from the ISCHEMIA
trial and therefore from the CIAO study.
INOCA may be due to microvascular dysfunction causing supply-demand mismatch,
inadequate vasodilation in response to increased demand and/or epicardial or microvascular
coronary spasm.35 These entities may occur in the presence or absence of coronary
atherosclerosis. Their dynamic nature over time may explain the substantial improvement in
ischemia and angina in our INOCA patients. For example, changes in coronary flow reserve
(CFR) over time in INOCA patients have been demonstrated in previous studies, with and
without anti-anginal treatment.36, 37,38 Coronary artery spasm, present in 39% of INOCA patients
in the Coronary Microvascular Angina (CorMicA) study, is inherently variable in relation to
Downloaded from http://ahajournals.org by on July 20, 2021

circadian rhythms, temperature and other factors.10, 39 Exercise stress testing is frequently
abnormal in cases of epicardial spasm and microvascular spasm.40, 41 The lack of correlation
between change in ischemia on stress echocardiography and change in angina severity is
consistent with a smaller study showing no relationship between 1-year changes in coronary flow
reserve and angina severity.42 Our observations may reflect peak disease activity at the time of
initial stress testing. Clinicians often order stress tests when symptoms are new or worsening.
Our observed improvement in angina over time is consistent with prior studies, including within
placebo arms in clinical trials.43 It is also possible that INOCA patients experienced less angina
over time due in part to reassurance by their physicians owing to the absence of obstructive
CAD, or due to lifestyle modifications. It remains possible that at least some patients included in
CIAO had false positive stress testing and therefore did not have INOCA.
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In CIAO, we did not perform invasive testing of coronary flow in response to vasoactive
stimuli, but such testing is typically recommended only for patients with persistent symptoms not
responsive to medical therapy.44 Invasive testing in unselected patients referred for cardiac
catheterization and found to have nonobstructive CAD demonstrated objective abnormalities in
the majority of patients tested in the CorMicA trial (89%), similar to results of testing in the
Women’s Ischemia Syndrome Evaluation (WISE, 78%) and a Mayo Clinic cohort (66%).10,11,12
A positive stress test increased the likelihood of microvascular dysfunction or spasm, but typical
rather than atypical chest pain did not.10, 40, 41 Interestingly, the majority of our patients in CIAO
and in ISCHEMIA did not report limiting chest pain during their initial stress test. Based on this
literature, the ischemia severity required for study entry, and the high reproducibility of blinded
stress echocardiographic assessments at the ISCHEMIA core laboratory, we believe our INOCA
participants had true myocardial ischemia. However, we cannot prove this in the absence of
Downloaded from http://ahajournals.org by on July 20, 2021

invasive testing.
The pathophysiology of angina is complex, with contributions not only from conditions
that limit blood flow at the epicardial vessel and/or microvascular level but also the intensity of
daily physical and mental activities that may provoke angina, diastolic function, myocardial wall
stress, autonomic nervous system function, patient-specific pain sensitivity, oxygen carrying
capacity and other factors, including patient sex.45 We found no significant correlation between
ischemia severity on stress echocardiography and angina frequency or overall angina-related
health status at enrollment in patients selected for moderate or severe ischemia, either with
INOCA or with obstructive CAD. Data from the WISE Study have also shown similar angina
frequency and quality of life in INOCA patients with and without ischemia on noninvasive
testing, and in those with CAD.46 It is possible that some patients with persistent ischemia on
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stress echocardiography undertook lifestyle changes (such as reducing physical activity or
emotional stress to avoid angina), leading to a disconnect between changes in day-to-day
symptoms and objective, inducible wall motion abnormalities of this degree on stress
echocardiography in follow up. For example, the majority of patients with and without
obstructive CAD did not report limiting chest pain during their initial stress test. In support of
this hypothesis is the correlation we observed between improvements in ischemia and the SAQ
physical limitation subscale over time. Conversely, changes such as adaptation to exercise or
changes in microvascular function may lead to improvement in inducible ischemia on stress
echocardiography, even as emotional stress may continue to provoke symptoms. In the case of
episodic coronary spasm, a lack of correlation between ischemia at the time of stress testing and
angina severity over the preceding four weeks is logical given the episodic nature of the disorder.
Additional research into these relationships in patients with and without obstructive CAD is
Downloaded from http://ahajournals.org by on July 20, 2021

needed.
We explored the relationship between medication use, improvement in angina and
improvement in ischemia, recognizing the limitations of our small sample size and the
observational nature of our study. We did not identify any medication class associated with
improvement in angina-related health status or ischemia severity over 1 year, but power is
limited and our comparisons were not randomized. The ACEI quinapril was previously shown in
a small randomized trial to reduce angina in women with INOCA, mediated in that study at least
in part by improvement in coronary flow reserve over 16 weeks.47 ACEI/ARB and statin therapy
are the subject of an ongoing large clinical trial in INOCA (NCT03417388). Diabetes was
associated with improvement in ischemia on stress echocardiography over 1 year in this study,
for unclear reasons.
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The rate of major adverse cardiovascular events (MACE) over 1 year in our cohort,
approximately 2%, is consistent with meta-analyses of outcomes in INOCA48 and with the event
rates in prior reports showing up to fourfold increased risk of cardiovascular events in patients
with symptoms prompting angiography showing no obstructive CAD as compared to healthy
people in the community, and lower risk in INOCA than in patients with obstructive CAD.3, 5, 17,
49-51

The rate of MACE or chest pain hospitalization was approximately 4% in one year,

consistent with the 20% rate of chest pain hospitalization over 5 years in the WISE, in which
associated high healthcare costs were high.9 Analysis of event rates in CIAO was considered
exploratory based on limited sample size and 1-year duration of follow up.
Our study must be interpreted in the context of several limitations. The link with the
parent ISCHEMIA trial is both a strength and limitation: inclusion of many centers increases
generalizability, and interpretation of stress tests at a core laboratory blinded to obstructive CAD
Downloaded from http://ahajournals.org by on July 20, 2021

status and timing is a strength. The CIAO sample is relatively large and incorporated systematic,
longitudinal assessments. However, patients in CIAO were excluded from ISCHEMIA
randomization in ISCHEMIA and therefore did not undergo invasive testing to confirm ischemia
or the lack of ≥50% stenosis. Angina was less frequent than in CorMicA because we excluded
patients with an unacceptable degree of angina from ISCHEMIA (and thus CIAO), to focus on
patients who would be suitable for randomization. ISCHEMIA participants were not required to
have anginal symptoms, but 90% did.21 Enrollment per site was low, reflecting the requirement
for moderate or severe ischemia as in the ISCHEMIA trial. The SAQ is phrased in terms of chest
pain, chest tightness or angina, and it is possible that some patients with atypical ischemic
symptoms did not convey the full severity of their symptoms in their responses. However, the
SAQ has been validated in women with ischemic heart disease and in patients with myocardial
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infarction with no obstructive CAD (MINOCA).52 The SAQ assesses symptoms over the
preceding month, but there was typically more than 1 month between stress testing and angina
assessment; interim changes in symptoms could have biased our results to the null. There could
have been regression to the mean in angina over time. Analysis of events is considered
exploratory based on our small sample size. Finally, this was an observational, non-randomized
study. We did not specify medical therapy in the protocol or collect doses, so analyses
incorporating medical therapy are limited by the potential for confounding. Future analyses of
ISCHEMIA study data will evaluate predictors of no obstructive CAD on study CCTA in a
larger sample incorporating multiple stress test modalities.
In conclusion, in this well-characterized, predominantly female cohort of patients with
significant ischemia on stress echocardiography as determined by a blinded core laboratory,
predominantly mild angina, and no obstructive CAD, half had resolution of stress-induced wall
Downloaded from http://ahajournals.org by on July 20, 2021

motion abnormalities on repeat stress echocardiography at 1 year and symptoms improved in
43%. There was no significant correlation between change in angina and change in ischemia on
stress echocardiography. Further research is needed to improve understanding of mechanisms
and define how best to manage symptoms in patients with INOCA to improve patient-centered
outcomes.
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Table 1. Demographics and clinical history in INOCA participants in CIAO and in ISCHEMIA stress
echocardiography participants with obstructive CAD on coronary CT angiography
Age, years (median (Q1,Q3))
Female Sex
Race/Ethnicity
Non-Hispanic White (n, %)
Non-Hispanic Asian (n, %)
Non-Hispanic Black (n, %)
Hispanic (n, %)
Other (n, %)
Body Mass Index, median (Q1,Q3)
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Estimated glomerular filtration rate (ml/min), median (Q1,Q3)
Hypertension n (%)
Diabetes (%)
Cigarette Smoking (n, %)
Never Smoked (%)
Former Smoker (%)
Current Smoker (%)
Prior MI (%)
Prior HF (%)
Valvular heart disease (%)
Atrial fibrillation or flutter (%)
Chronic lung disease (%)
Malignancy (%)
Anxiety (%)
Depression (%)
Gastroesophageal reflux disease (%)
Cardiac catheterization before ISCHEMIA enrollment (%)
Time between stress echo and enrollment in ISCHEMIA,
days, median (Q1,Q3)
Time between enrollment in ISCHEMIA and CIAO, days,
median (Q1,Q3)
Number of segments with stress-induced moderate or severe
wall motion abnormalities, median (Q1,Q3)
Stress wall motion score index
Ischemia Location
Anterior
Inferior
Lateral
Stress type
Exercise
Symptoms during stress
No
Yes
Limiting Exertional Chest pain

30

INOCA
N=208
62.5 (56.0, 70.0)
137 (66%)
N=208
151 (73%)
14 (7%)
10 (5%)
25 (12%)
8 (4%)
n=195
28.7 (25.4, 32.9)
86 (76,97)
132/207 (64%)
40/208 (19%)
n=181
107 (59%)
53 (29%)
21 (12%)
4/208 (2%)
5/207 (2%)
9/204 (4%)
9/206 (4%)
9/206 (4%)
8/206 (4%)
27/206 (13%)
40/206 (19%)
33/206 (16%)
9/208 (4%)
n=206
10 (3-23)
n=208
41 (24-91)

Obstructive CAD
N=865
65.7 (59.4, 71.7)
221 (26%)
N=824
434 (53%)
151 (18%)
17 (2%)
217 (26%)
5 (0.6%)
n=852
28.1 (25.6, 31.4)
86 (72,100)
585/857 (68%)
281/865 (33%)
n=864
380 (44%)
348 (40%)
136 (16%)
129/860 (15%)
21/865 (2%)
21/809 (3%)
19/864 (2%)
69/865 (8%)
48/864 (6%)
NA
80/861 (9%)
NA
214/865 (25%)
n=865
11 (4-26)
NA

NA

4 (3-5)

4 (3-5)

0.012

N=206
1.2 (1.1, 1.2)
n=208
91 (44%)
87 (42%)
68 (33%)

N=865
1.3 (1.1,1.5)
n=865
304 (35%)
662 (77%)
571 (66%)

<0.001

167/205 (82%)
n=200
91 (45.5%)
109 (54.5%)
21 (19%)

621/760 (82%)
n=721
285 (40%)
436 (61%)
122 (29%)

>0.99
<0.001
0.15

p
0.001
<0.001

<0.001

0.09
0.52
0.25
<0.001

0.001
<0.001
>0.99
0.26
0.13
0.10
0.43
NA
<0.001
NA
<0.001
0.61

0.027
<0.001
<0.001

0.06
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Non-Limiting Exertional Chest pain
22 (20%)
138 (32%)
0.02
Dyspnea
49 (45%)
123 (29%)
0.002
Claudication
1 (1%)
4 (1%)
>0.99
Other
15 (14%)
33 (8%)
0.08
Unknown
1 (1%)
6 (1%)
>0.99
NA=not applicable
Indications for initial stress testing in CIAO participants (not mutually exclusive; total is greater than 100%) were:
typical angina (n=104, 50%), atypical chest pain (n=67, 32%), shortness of breath (n=102, 49%), discomfort in the
arm, neck, jaw or throat (n=17, 8%), abdominal discomfort (n=6, 3%), fatigue (n=29, 14%), nausea or other
gastrointestinal upset (n=5, 2%), sweating (n=9, 4%), screening with no symptoms (n=4, 2%), other (n=3, 1%).
Indication for initial stress testing was not collected in ISCHEMIA participants.
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Table 2. Findings on stress echocardiography at enrollment and at 1 year in INOCA patients in CIAO
INOCA enrollment
N=208
4 (3,5)
N=206
1.2 (1.1, 1.2)
n=205
40 (100%)
167 (81%)
n=201
148 (137,158)

INOCA 1-year
N=194
0 (0,2)
N=192
1.0 (1.0, 1.1)
n=193
4 (22%)
149 (77%)
n=192
144 (131,157)

p enrollment
vs. 1 year
<0.001
<0.001

% of maximal predicted heart rate achieved, median (Q1,Q3)

91.6 (86.3, 98.6)

89.5 (85.0, 98.7)

0.014

Peak heart rate ≥ 85% of maximal predicted heart rate

163 (81%)
n=194
140 (123,150)
n=165
80 (76,89)
n=195
170 (150,190)
n=167
83 (79,93)
n=167
116 (69%)
n=116
364 (282, 503)
n=157
7.0 (6.0, 9.3)
60/206 (29%)
n=60
1.00 (1.00,1.70)
n=208
91 (44%)

144 (75%)
n=193
133 (120,149)
n=193
80 (72,89)
n=193
170 (150,191)
n=193
84 (73,104)
n=149
112 (75%)
n=110
410 (302, 511.5)
n=123
7.8 (6.3,10.1)
41/194 (21%)
n=41
1.00 (1.00,1.50)
n=194
28 (15%)

0.049

48 (23%)

12 (6%)

<0.001

Number of ischemic segments, median (Q1,Q3)
Stress wall motion score index, median (Q1, Q3)
Type of stress*
Dobutamine (%)
Exercise (%)
Peak heart rate

Baseline systolic blood pressure
Baseline diastolic blood pressure
Peak systolic blood pressure
Peak diastolic blood pressure
Exercise testing parameters
Standard Bruce protocol (%)
Average time on standard Bruce protocol (seconds), median (Q1, Q3)
Peak METs achieved
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ST segment depression present (%)
Peak severity of ST segment depression, mm, median (Q1, Q3)

Echocardiographic location of ischemia
Anterior ischemia (%)
Moderate anterior ischemia (≥3 ischemic segments in anterior territory, n)

0.013

0.18

0.16
0.003
0.57
0.17
0.50
0.003
0.065
<0.001
0.92
<0.001

Lateral ischemia (n)
68 (33%)
12 (6%)
<0.001
Inferior ischemia (n)
87 (42%)
25 (13%)
<0.001
Normal study, %
15 (7.2%)
107 (55%)
<0.001
Symptoms during stress
n=200
n=193
No
91 (45%)
123 (64%)
<0.001
Yes
109 (55%)
70 (36%)
Limiting Exertional Chest pain
21 (19%)
4 (5.7%)
<0.001
Non-Limiting Exertional Chest pain
22 (20%)
16 (23%)
0.049
Dyspnea
49 (45%)
36 (51%)
0.073
Claudication
1 (1%)
0 (0%)
NA
Other
15 (14%)
29 (15%)
0.17
Unknown
1 (0.9%)
0 (0%)
NA
*2 participants who had qualifying exercise stress echocardiography underwent dobutamine stress echocardiography in follow up, and 2
participants who had qualifying dobutamine stress
Median time from initial to follow up stress echocardiography 320 days (Q1,Q3 261-357). There were no complications of study stress testing.
Ischemia location does not add to 100% because participants could have ischemia in multiple coronary territories. Ischemia in each of the
anterior, inferior or lateral locations required two segments with stress-induced wall motion abnormalities in the territory as defined by the
American Society of Echocardiography segmentation model. Moderate anterior ischemia was defined as at least 3 segments with stress-induced
wall motion abnormalities in the left anterior descending coronary artery territory.
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Table 3. Symptoms at enrollment, 6 months and 1 year in CIAO with INOCA and at randomization in ISCHEMIA
stress echocardiography participants with CAD on coronary CT angiography
Obstructive CAD at
enrollment (N=865)
SAQ-7, median (Q1,Q3)
Seattle angina questionnaire angina
frequency score – median (Q1,Q3)
No angina in last month (SAQ AF = 100 at
the time of CIAO enrollment, %)
Monthly angina (SAQ AF = 61-99 at the
time of CIAO enrollment, %)
Weekly angina (SAQ AF = 31-60 at the
time of CIAO enrollment, %)
Daily angina (SAQ AF = 0-30 at the time of
CIAO enrollment, %)
Seattle angina questionnaire physical
limitation score – median (Q1,Q3)
SAQ quality of life score, median (Q1,Q3)

INOCA 6
months
(N=160)
92 (76,100)
100 (80,100)

INOCA 1 year
(N=197)

P (INOCA across
all 3 time points)

78 (64,92)
N=859
100 (90, 100)
534 (62%)

INOCA at
enrollment
(N=203)
83 (66,93)*
N=201
90 (70,100)*
81 (40%)

90 (77,100)
100 (80,100)

<0.001

94 (59%)

117 (59%)

293 (34%)

86 (43%)

55 (34%)

64 (32%)

31 (3.6%)

29 (14%)

11 (6.9%)

15 (8%)

5 (0.6%)

5 (2%)

0 (0%)

1 (1%)

N=806
100 (67, 100)
N=859
63 (50, 88)
N=716
8 (3,36)
504/847 (60%)
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N=190
N=154
N=184
<0.001
92 (75,100)
92 (75,100)
100 (75,100)
N=201
N=160
N=196
<0.001
75 (50, 100) 88 (63, 100) 88 (63, 100)
Time since first diagnosis of angina (months)
N=145
8 (3,18)
Dyspnea present by Rose Dyspnea
130/202
96 (60%)
114 (58%)
<0.001
Questionnaire
(64%)*
Overall health score, median out of 100
N=842
N=196
N=158
N=196
<0.001
(Q1,Q3)
80 (70, 90)
75 (60, 81)* 80 (65, 85)
80 (70, 90)
* P<0.05 for comparison between obstructive CAD and INOCA participants at the time of enrollment. For SAQ-7, p=0.04; for SAQ AF and
Rose Dyspnea Scale, p<0.001; for overall health score, p=0.01.
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Figure Legends

Figure 1. CONSORT diagram.
CIAO eligibility was restricted to stress echocardiography to avoid the additional radiation
exposure required for stress nuclear imaging in follow up. Stress CMR was used infrequently in
ISCHEMIA and was not included in CIAO to minimize heterogeneity. The most common
reasons for clinical ineligibility were prior revascularization indicating history of obstructive
CAD (n=12), normal stress echocardiogram (n=10) and no ischemic symptoms (n=7).
ISCHEMIA stress echocardiography participants were enrolled between July 2012-January 2018
in 21 (of 37 total) countries. Most, but not all ISCHEMIA participants had CCTA done before
randomization. Among 1,081 randomized participants who had stress echo, 865 had CCTA
showing obstructive CAD and 216 did not undergo CCTA. Recruitment was completed when all
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candidates for CIAO enrollment among ISCHEMIA trial screen failures had been considered.
SAQ was missing at baseline in 5 and at 1 year in 11. 1-year stress echocardiography was
missing in 16 (not mutually exclusive from missing SAQ).

Figure 2. Ischemia severity, angina severity and their correlation in INOCA and CAD at
enrollment.
Panels A-B. Distribution of the number of ischemic segments on enrollment stress
echocardiography for CIAO participants with INOCA (A) and ISCHEMIA participants with
CAD on study coronary CT angiogram (B).
Panels C-D. Distribution of Angina Frequency (AF) scores on the Seattle Angina Questionnaire
(SAQ) at enrollment in participants with INOCA (C) and CAD (D)
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Panels E-F. Distribution of Seattle Angina Questionnaire (SAQ) summary scores at enrollment
in participants with INOCA (E) and CAD (F).
Panels G-H. Distribution of ischemia severity categories as compared with SAQ AF score
categories in participants with INOCA (G) and CAD (H). When SAQ AF was analyzed as a
continuous variable, there was also no significant correlation: rho=0.105, p=0.15 for INOCA and
rho=0.027, p=0.42, respectively.
Only ISCHEMIA participants who qualified for the trial based on stress echocardiography and
underwent coronary CT angiography showing at least 1 vessel with ≥50% stenosis are included
here. Number of ischemic segments reflects core laboratory determination. Ischemia severity
was mild if there were 1-2 ischemic segments, moderate if there were 3 ischemic segments, and
severe if there were 4 or more ischemic segments. Participants in ISCHEMIA were permitted to
enroll in CIAO before core laboratory confirmation of ischemia severity, to be consistent with
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the main trial, so some INOCA participants had less than 3 ischemic segments per core
laboratory assessment. The interpretation of SAQ scores is depicted on the figure. The median
time between stress echocardiography and angina assessment was similar for INOCA and CAD
participants (Table 1). ISCHEMIA stress echocardiography participants with CAD had similar
angina frequency (median 90, IQR 70-100, p=0.22, Figure 2 and Table 3) but poorer SAQ
summary scores (ISCHEMIA median 77, IQR 63-92, CIAO median 83, IQR 66-93, p=0.019) at
baseline. Median overall health status was rated by INOCA participants as 75 (IQR 60,81) on a
scale of 100 on the EQ-5D, indicating, on average, good health status. There was also no
correlation between SAQ summary score or angina frequency score and number of ischemic
segments when considering SAQ scores as continuous rather than categorical measures.
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Figure 3. Change in number of ischemic segments from enrollment to 1 year in INOCA.
Panel A. Change in the number of ischemic segments on stress echocardiography from
enrollment to 1 year.
Panel B. Number of ischemic segments at enrollment.
Panel C. Number of ischemic segments at 1 year.

Figure 4. Change in angina vs. change in ischemia in INOCA, in relation to 1-year stress
echo findings
Panels A and B show SAQ scores at enrollment (SAQ AF score, panel A, and SAQ summary
score, panel B), 6 months, and 1 year in relation to improvement in the number of ischemic
segments on stress echocardiography by at least 2 segments from enrollment to 1 year.
Panels C and D. Correlation between change in the number of ischemic segments and change in
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SAQ angina frequency (C); and change in SAQ summary score (D). The median SAQ summary
score was 90 (IQR 77-100) and median angina frequency score was 100 at 1 year (IQR 80-100,
p<0.001 across all 3 time points, Table 3). Overall health status was rated similarly to that at
enrollment, median 80 of 100 (IQR 70-90, p=<0.001 across all 3 time points). There was no
correlation between the SAQ physical limitation subscale score and the number of ischemic
segments at enrollment (rho =-0.03, p=0.69). There was no significant correlation between the
SAQ summary score or any subscale score at 1 year and the number of ischemic segments at 1
year.
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